Preclinical Development Stocks
Biotechnology firms in this cohort operate at the high-risk intersection of drug discovery and early-stage validation, focusing on asset optimization prior to human clinical trials.
As of Oct 23, 2026, Preclinical Development has 16 US-listed companies worth $18.6B combined. The median member moved -1.2% over the past week; REVB led at +681.9% and SLBT trailed at -24.8%.
Companies in Preclinical Development
- CRL – Charles River Laboratories, $16.6B
- SLBT – SL Science Holding Limited Ordinary Shares, $869M
- PRME – Prime Medicine, Inc. Common Stock, $707M
- CNXU – Conexeu Sciences Inc. Common Stock, $93.4M
- TELO – Telomir Pharmaceuticals, Inc. Common Stock, $80.2M
- IBIO – iBio, Inc. Common Stock, $72.3M
- CSBR – Champions Oncology Inc, $66.9M
- EXOZ – eXoZymes, Inc., $38.3M
- MGX – Metagenomi, Inc. Common Stock, $37.8M
- ERNA – Eterna Therapeutics Inc, $3.7M
- REVB – Revelation Biosciences Inc, $3.3M
- DCOY – Decoy Therapeutics Inc., $2.8M
- NXTS – Nexentis Technologies Inc., $948,735
- OCEA – Ocean Biomedical Inc., $185,892
- VRPX – Virpax Pharmaceuticals Inc, $248
- NEXI – Neximmune Inc, $139